Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude
Sponsor: University of California, Riverside
Summary
High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.
Official title: The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude: a Randomized Cross-over Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
19
Start Date
2025-09-17
Completion Date
2026-12-15
Last Updated
2026-04-08
Healthy Volunteers
Yes
Interventions
ACETAZOLAMIDE oral capsule
Acetazolamide is administered orally in pill form at a 125 mg dose taken twice per day (morning and evening) starting 2 days before ascent to high altitude and each day while at high altitude.
Placebo Arm
Not utilization of Acetazolamide (ACZ) oxygenation (SpO2) or any other supportive measurement will be used with this group.
Locations (1)
University of California, Riverside
Riverside, California, United States